Postmenopausal women show the highest incidence of
breast cancer in the female population and are often affected by
metabolic syndrome.
Metabolic syndrome (MS)--characterized by central adiposity,
insulin resistance, low serum
high-density lipoprotein cholesterol (HDL-C), high serum
triglyceride and
high blood pressure--seems to be strictly correlated to breast
carcinogenesis. We enrolled 777 healthy women and women with
breast cancer in our nested case-control study to evaluate the association between MS and
breast cancer, analyzing anthropometric parameters (weight, height, BMI, waist and hip circumference), blood pressure, serum HDL-C,
triglyceride, fasting plasma
glucose,
insulin,
testosterone and
uric acid levels and administering a questionnaire about physical activity, food intake, tobacco use,
alcohol abuse, personal and familial history of disease. We found an higher prevalence of
metabolic syndrome (30%) in postmenopausal
breast cancer patients compared to healthy women (19%). None of the individual MS features was strong enough to be considered responsible for breast
carcinogenesis alone. However, of the 63 postmenopausal
breast cancer cases associated to MS, 30% presented three or more MS features, suggesting that the activation of multiple molecular pathways underlying MS might contribute to
tumorigenesis. Our data support the hypothesis that MS may be an
indicator of
breast cancer risk in postmenopausal women. The unsettlement of the hormonal arrangement in postmenopausal, along with an increase in visceral adiposity, probably favour the
hormone-dependent cell proliferation, which drives
tumorigenesis. Adjustments in lifestyle with physical activity intensification and healthy diet could represent modifiable factors for the primary prevention of sporadic
breast cancer.